Generic name: procainamide hydrochloride
Dosage form: Extended Release Tablets
Medically reviewed on October 10, 2017.
The dose should be adjusted for the individual patient, based on clinical assessment of the degree of underlying myocardial disease, the patient's age, and renal function. For patients who have been receiving another formulation of procainamide, the dose of the other formulation can function as a general guide, but re-titration with Procanbid® is recommended.
As a general guide, for younger patients with normal renal function, an initial total daily oral dose of up to 50 mg/kg of body weight of Procanbid® tablets may be used, given in 2 divided doses, every 12 hours, to maintain therapeutic blood concentrations. For older patients, especially those over 50 years of age, or for patients with renal, hepatic, or cardiac insufficiency, lesser amounts or longer intervals may produce adequate blood concentrations, and decrease the probability of occurrence of dose-related adverse reactions.
CARE SHOULD BE TAKEN WHEN DISPENSING Procanbid® TO ASSURE THE BID DOSAGE FORM HAS BEEN PRESCRIBED AND DISPENSED. Procanbid® tablets should be swallowed whole and should not be bitten or cut.
To provide up to 50 mg/kg of body weight per day*
|88–110 lb (40–50 kg)||1000 mg q12 hrs|
|132–154 lb (60–70 kg)||1500 mg q12 hrs|
|176–198 lb (80–90 kg)||2000 mg q12 hrs|
|>220 lb (>100 kg)||2500 mg q12 hrs|
*Initial dosage schedule guide only, to be adjusted for each patient individually, based on age, cardiorenal function, blood concentration (if available), and clinical response.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about Procanbid (procainamide)
- Procanbid Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- 0 Reviews
- Drug class: group I antiarrhythmics
Other brands: Pronestyl